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Renal hypertrophy and accumulation of extracellular matrix proteins are among cardinal manifestations of diabetic nephropathy.
TGF beta system has been implicated in the pathogenesis of these manifestations. Among signaling pathways activated in the
kidney in diabetes, mTOR- (mammalian target of rapamycin-)regulated pathways are pivotal in orchestrating high glucose-
induced production of ECM proteins leading to functional and structural changes in the kidney culminating in adverse outcomes.
Understanding signaling pathways that inﬂuence individual matrix protein expression could lead to the development of new
interventional strategies. This paper will highlight some of the diverse components of the signaling network stimulated by
hyperglycemia with an emphasis on extracellular matrix protein metabolism in the kidney in diabetes.
1.Introduction
The importance of hyperglycemia in renal injury was con-
ﬁrmed by the Diabetes Control and Complications Trial [1]
and the United Kingdom Prospective Diabetes Study [2],
which demonstrated that diabetic kidney disease can be pre-
vented by keeping blood sugar in target range; however, this
is diﬃcult to achieve. Diabetes, particularly type 2, is the
most common cause of end-stage renal disease requiring
chronic renal replacement therapy in the US. Despite its high
prevalence, the mechanism of development and progression
of diabetic nephropathy (DN) is still not fully understood,
partly because of unrecognized and undiagnosed kidney
changes that coexist during latent diabetes [3]. Much of
our understanding of the mechanisms of injury in diabetes
comes from studies on rodent models of diabetes. Although
severalsuchanimalmodelsofdiabetesexist,nosingleanimal
model develops renal changes identical to those seen in
h u m a n s .B r o s i u se ta l .[ 4] have compiled a report on the
progress towards establishing and validating a murine model
of human DN (http://www.diacomp.org/). It is likely to be
diﬃcult to generate a single mouse model that recapitulates
all of the features of human DN.
Pathophysiology of DN involves an interaction of ge-
netic, metabolic, and hemodynamic factors. Structural renal
changes in diabetes start with glomerular hypertrophy, fol-
lowed by glomerular basement membrane (GBM) thicken-
ing, mesangial matrix expansion, and development of scle-
rotic lesions [5]. Accumulation of extracellular matrix pro-
teins is governed by a balance between increased synthesis
regulated at the level of transcription and mRNA translation,
and, degradation regulated by such processes as the balance
between proteolytic activity of matrix metalloproteinases
(MMPs) and their inhibitors, the tissue inhibitor of met-
alloproteinases (TIMPs). A variety of growth factors and
cytokines participate in this pathology through complex sig-
nal transduction pathways in a cell-speciﬁc manner. In this
review we will discuss the various mechanisms by which
hyperglycemia can induce extracellular matrix synthesis and
accumulation in diabetic kidneys.
2.ExtracellularMatrix Components
An early sign of renal involvement in diabetes is an increase
in basement membrane thickness that has been described as
a prediabetic lesion [6]. The thickening of the renal base-
ment membranes of the glomerulus (GBM) and tubules2 Experimental Diabetes Research
(TBM) is due to a consequence of the hyperglycemia-
induced metabolic perturbations resulting in augmented
synthesis and accumulation of intrinsic ECM components at
these sites [7, 8]. The major TBM components are type IV
collagen, laminin, and entactin while collagen types I, V, and
VI and ﬁbronectin are generally considered components of
the renal interstitium. The GBM is predominantly composed
of laminin, collagen type IV alpha 3 to alpha 5, agrin, and
perlecan. In diabetes it has been shown that collagen α3
through α5(IV)chains,collagenV,laminin,ﬁbronectin,and
serum proteins contribute to thickened GBM [9]. Mesangial
expansion is largely due to the accumulation of extracellular
matrix (ECM) proteins such as collagen α1, α2 (IV) chains,
collagens V and VI, laminin, and ﬁbronectin [10, 11].
2.1. Laminins. Laminins are glycoproteins expressed pri-
marily in basement membrane. Laminins are heterotrimeric
structures consisting of combinations of ﬁve alpha, three
beta, and three gamma chains that share a common domain
and several globular and rod-like domains. The tissue-
speciﬁc distribution of laminins is mainly determined by
expression of the alpha chains; in particular, a number
of alpha 5-chain mutations are associated with neonatal
lethalityanddefectiveglomerulogenesis[12,13].Glomerular
and proximal tubular epithelial cell laminin expression
has been shown to increase in response to hyperglycemia
and TGF-b coincident with increased thickening of the
glomerular basement membrane [14, 15].
2.2. Collagen Type IV. Collagens serve as ﬁbrotic markers in
diabeticnephropathy,andtypeIVcollagenprovidesthebasic
structural framework of the glomerular ECM. There are six
genetically distinct alpha chains (α1 through α6), and all
have similar domain structures. In the GBM alpha 3 through
alpha 5 predominate whereas in the TBM alpha 1, 2, 3, and 5
are present [16, 17].
2.3. Fibronectin. Fibronectin is a glycoprotein that is found
in the plasma as well as in the basement membrane and
the mesangium of the glomerulus [18, 19]. Types V and
VI collagen along with type IV, and ﬁbronectin colocalize
in a similar distribution in the glomerular subendothelial
area and the mesangium. Entactin/nidogen (En/Nd) is
an elongated approximately 150kDa molecule containing
three globular domains separated by two linear segments.
Laminin, type IV collagen, and ﬁbronectin are all capable
of self-aggregation. Laminin also has additional binding sites
for glycosaminoglycans and attaches to collagen via nidogen
bridge. It serves as a link between the laminin and collagen
IV networks in sub-endothelial, subepithelial and mesangial
areas in the glomerular basement membranes [20, 21]. The
networkingpatternoftheseECMcomponentsdeterminethe
pore size and the charge-selective properties of GBM [22].
3. Role of Transcription,mRNA Translation,
andRibosomeBiogenesisinECMProduction
3.1.Transcription. Regulationofproteinsynthesismayoccur
at the level of transcription or mRNA translation. High
glucose stimulates the transcription of matrix genes and
represses matrix degradation leading to glomerulosclerosis
[23–25]. Sanchez and Sharma [26]h a v ee x t e n s i v e l yr e vi e w e d
themechanismofactivationoftranscriptionfactorsinvolved
in the progression of diabetic kidney disease including
upstream stimulatory factors (USF1 and 2), activator protein
1 (AP-1), cAMP-response element-binding protein (CREB),
nuclear factor (NF)-κB, nuclear factor of activated T
cells (NFAT), and stimulating protein 1 (Sp1). Until the
beginning of the last decade transcription was the only
studied regulatory mechanism for increased ECM protein
synthesis induced by hyperglycemia in the renal tissues.
Accumulating evidence from recent studies has established
mRNA translation as another important and independent
step in the regulation of protein synthesis [27–30].
3.2. mRNA Translation. The process of mRNA translation
occurs in three steps: the initiation phase, which involves
localization of the preinitiation complex containing the 40S
ribosomal subunit and the initiator methionyl tRNA to the
AUG (methionine) codon on the mRNA; the elongation
phase, during which amino acids are added to the nascent
peptide according the codon sequence of the mRNA; the
termination phase, in which arrival at a stop codon leads to
the release of the completed peptide chain. Of these three
steps, initiation is the rate limiting step as it determines the
recruitment of ribosomes to the speciﬁc mRNA. Elongation
itselfiscomposedofthreetraditionallydeﬁnedsteps:eEF1A-
directed binding of the aminoacyl-tRNA to the A site
(aminoacyl site) of the ribosome, peptide bond formation
triggered by the enzymatic activity of the ribosome (the
peptidyl transferase center), and eEF2- mediated translo-
cation which moves the peptidyl-tRNA from the A site
to the P site (peptidyl site) by precisely one codon (three
nucleotides) [31–33]. Upregulation of these events result
in augmented translational eﬃciency. Signaling pathways
play a major role in regulation of translation. Among them
the mTOR system regulates the initiation and elongation
phases of translation of speciﬁc mRNAs to culminate in
increasedproteinsynthesis[31–33]. Suchcontrolis generally
exerted through changes in the phosphorylation states of the
translation initiation or elongation factors. Diabetic kidney
tissues and renal cells treated with high glucose demonstrate
activation of various initiation and elongation factors that
are involved in regulation of mRNA translation [14, 15, 34].
Activation of these factors by high glucose and angiotensin
II resulted in upregulation of selective proteins like laminin
beta 1 chain and vascular endothelial growth factor (VEGF),
respectively, in tubular epithelial cells [15, 35].
3.3. Ribosome Biogenesis. Ribosome biogenesis is a complex
well-coordinated process in which hundreds of diﬀerent
proteins interact in the folding and processing of ribosomal
RNA (rRNA) consisting of a small (40S) and large (80S)
subunit in eukaryotic cells. The large subunit is composed of
5S, 28S, 5.8S rRNAs whereas the 40S subunit contains 18S
rRNA. Furthermore, approximately 80 diﬀerent ribosomal
proteins(r-proteins)arefoundineukaryoticribosomes[36].
Ribosomesconsistingof80Sand40SribosomalsubunitsandExperimental Diabetes Research 3
ribosomal proteins are part of the translation machinery that
aid in carrying out the process of peptide synthesis by the
addition of amino acids through translation of the genetic
code in mRNA. The smaller (40S) subunit of the ribosome
serves as a platform to bring together messenger RNA, ami-
noacylated transfer RNAs, and translation factors. The larg-
er (80S) ribosomal subunit provides peptidyl transferase ac-
tivitytocatalyzepeptidebondformationinnascentpolypep-
tides. Increased production of ribosome reﬂects enhanced
capacity for translation. Ribosome biogenesis is so impor-
tant for cell growth that a growing yeast cell synthesizes
approximately 2000 ribosomes every minute, requiring 60%
of total cellular transcription. In mammalian cells [37], this
number is even higher; for example, a HeLa cell makes 7500
ribosomal subunits per minute [38]. Ribosome biogenesis is
regulatedbytheactivityofRNApolymeraseI,whichcontrols
the rate of rRNA synthesis. The activity of RNA polymerase I
at the ribosomal DNA promoter is modulated by a complex
of proteins, which includes the nucleolar protein upstream
binding factor (UBF) 1. UBF1 interacts with the protein
complex TIF-1B (SL1 in humans), which consists of the
TATA box-binding protein and three associated factors. The
resulting complex promotes the binding of RNA polymerase
I to the ribosomal DNA promoter [39, 40]. The activity of
UBF1 is regulated, at least in part, by its phosphorylation at
Serine 388 [41]. We observed increased UBF phosphoryla-
tionatSer388accompaniedbyincreasedrDNAtranscription
in glomerular epithelial cells treated with high glucose and in
kidney tissues from type 2 diabetic mice model [42]. This
eventually leads to increased rRNA molecules and ribosomal
proteinstherebyincreasingtranslationalcapacityandsetsthe
stage for increased matrix protein synthesis in renal tissues
and cells in response to hyperglycemia.
4.Signaling Pathways Activators and Inhibitors
of ProteinSynthesis
4.1. mTOR. At the molecular level, mTOR is recognized as
themediatorofsignalsfromextracellularhighglucosemilieu
tothenuclearcontentsofthecell.Thecomplexsignalingcas-
cade regulated by high glucose to induce extracellular ma-
trix protein synthesis is summarized in Figure 1.m T O Re x -
ists in two distinct physical and functional complexes,
namely, mTORC1 and mTORC2 [43]. mTORC1 comprises
mTOR, raptor, and mLST8; it phosphorylates the translation
initiation regulators, p70S6 kinase and 4E-BP1, resulting in
the changes in the activity of a number of initiation and
elongation factors [44, 45]. In the resting cell, eukaryotic
initiation factor 4E (eIF4E) is held inactive by its binding
protein, 4E-BP1 [46]. When a stimulus for protein synthesis
is received, mTORC1 is activated and it phosphorylates 4E-
BP1. Phosphorylation of 4E-BP1 results in dissociation of
eIF4E-4E-BP1 complex and release of eIF4E which then
binds to the cap of the mRNA [47–50]. This augments the
eﬃciency of translation. Phosphorylation of p70S6 kinase by
mTORC1 aﬀects both the initiation and elongation phases of
mRNA translation. Activated p70S6 kinase phosphorylates
ribosomal proteins and regulates ribosomal function. It
also phosphorylates eukaryotic elongation factor 2 kinase
(eEF2 kinase) which inhibits its activity [51, 52]. Decreased
activity of eEF2 kinase contributes to reduced phosphory-
lation of eEF2 which results in activation of the latter [53].
Asmentionedabove,activatedeEF2facilitatesthemovement
of aminoacyl tRNA from the A site to the P site on the ribo-
some during elongation phase of translation [51]. Thus,
activation of p70S6 kinase facilitates the addition of amino
acids to the newly synthesized peptide. Kidney tissues from
type 2 diabetic db/db m i c es h o w e da c t i v a t i o no fm T O R C 1
that coincides with renal hypertrophy and matrix expansion.
The constituents of the mesangial matrix expansion in the
db/db mouse kidney consist of increased type IV collagen,
ﬁbronectin, and laminin [54, 55]. We have reported increase
in laminin content in glomeruli and tubules by immunohis-
tochemistry and morphometry in db/db mice kidneys when
compared to db/m control mice; these diabetes-associated
changes were inhibited by rapamycin. Ameliorative eﬀect of
rapamycin was shown to be due to inhibition of mTORC1
and its downstream pathways regulating the elongation
phase of mRNA translation [34].
The mTORC2 complex contains mTOR, rictor, SIN1,
and mLST8. Recent work has revealed that it controls the
phosphorylation of the antiapoptotic proteins Akt/PKB and
serum and glucocorticoid inducible kinase (SGK) and may
promote cell survival [56–58]. Translation and processing of
nascent polypeptides are highly coupled events that result in
the production of mature and functional proteins. Recent
investigations show that while mTORC2 activation of Akt
and SGK1 can modulate translation, this complex also be-
comes recruited to the translating ribosome in order to
process the newly synthesized polypeptide [59, 60]. The ri-
bosome serves as a platform for cotranslational processing,
folding, and transporting proteins to their target sites [61].
Most studies so far have been based on pharmacological
inhibition of mTORC1 by rapamycin. Systemic adminis-
tration of rapamycin, a speciﬁc and potent inhibitor of
mTORC1, ameliorated pathological changes and renal dys-
function in diabetes [14, 62–65]. Thus, inactivation of
mTORC1 is protective and reduced the eﬀect of Erk- and
TGF-beta-mediated prosclerotic pathways. However, cell-
speciﬁc role of mTOR in renal hypertrophy induced by high
glucose remained to be explored. Recent work by G¨ odel et al.
[66] and Inoki et al. [67] shows that genetic reduction of
mTORC1 activity by eliminating 1 Raptor allele prevents
podocyte injury and ameliorates the progression of common
glomerular diseases such as diabetic nephropathy; mTORC1
activation induced by ablation of an upstream negative reg-
ulator Tsc1 recapitulated many DN features, including pod-
ocyte loss, glomerular basement membrane thickening, me-
sangial expansion, and proteinuria in nondiabetic mice.
Thus, mTORC1 remains an attractive target for potential
therapeutic target to prevent DN.
Increase in protein synthesis occurs not only by stimula-
tion of transcription and translation by also by inhibition of
moleculesthatinhibittheseprocesses.Signalingmechanisms
augmenting protein synthesis have received much attention
[14, 34, 62, 68, 69]. In contrast, constitutive signaling
mechanisms that counteract the prohypertrophic signaling
mechanisms and inhibit protein synthesis are not well4 Experimental Diabetes Research
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Figure 1: Intracellular signaling cascades regulated by high glucose leading to activation of promoters and suppression of intrinsicinhibitors
of protein synthesis. Grey pentagons show the positive regulators held in an inactive repressor complex with an inhibitory protein. mTORC2
role in high glucose-induced protein synthesis has to be determined.
understood. There are at least three important constitutive
inhibitors of protein synthesis. They are AMP-activated
protein kinase (AMPK) and Deptor that inhibit the activity
of mTOR and glycogen synthase kinase 3 beta (GSK 3β) that
inhibits the activity of eukaryotic initiation factor 2B epsilon
(eIF2Bε).
4.2. AMPK. AMPK plays a dual role in cell metabolism.
It serves as an energy sensor and as a part of AMPK-
TSC pathway, it inhibits Rheb/mTORC1 and keeps protein
synthesis in check. Hyperglycemia reduced AMPK activ-
ity by phosphorylation at Thr172 on the catalytic alpha
subunit resulting in activation of mTORC1 in glomerular
epithelial cells [14]. Activation of mTORC1 contributes to
the renal changes characteristic of DN, including glomeru-
lar hypertrophy, glomerular basement membrane (GBM)
thickening, and the accumulation of mesangial matrix [14,
70–72]. Inhibition of AMPK by high glucose is required
for high glucose-induced hypertrophy and ECM protein
increment. Treatment of neonatal rat cardiomyocytes and
renal glomerular epithelial cells with metformin, AICAR, or
resveratrol activated AMPK and inhibited the development
of hypertrophy induced by agents such as high glucose or
phenylephrine[14,71,73].Thus,AMPKcouldbeapotential
target for intervention in diabetic nephropathy.
4.3. GSK 3β. GSK 3β is a ubiquitously expressed, highly
conserved serine/threonine protein kinase found in all
eukaryotes. Unlike most protein kinases involved in sig-
naling, GSK 3β is active in unstimulated, resting cells and
it is inactivated upon phosphorylation at Serine 9. GSK
3β is inactivated during hypertrophy of skeletal myotube
[74], heart [75, 76] and pulmonary artery smooth muscle
[77]. GSK 3β phosphorylates its substrate eIF2B epsilon in
the resting cell [78]. Activity of eIF2B epsilon is important
for the formation of the preinitiation complex during the
initiation phase of mRNA translation [79]. We observed that
GSK 3β inhibits high glucose-induced protein synthesis in
renal proximal tubular epithelial cells and renal tissues by
inhibiting the activity of eIF2Bε [80]. Type 2 diabetic db/db
mice showed increased phosphorylation of renal cortical
GSK 3β and decreased phosphorylation of eIF2Bε,w h i c h
correlated with renal hypertrophy at 2 weeks, and increased
laminin β1 and ﬁbronectin protein content at 2 months.
These data raise the possibility that renal hypertrophy and
laminin β1 accumulation induced by type 2 diabetes could
be rescued by the activation of GSK 3β or by overexpression
of an active form of GSK 3β in the kidney in the db/db
mouse. In transgenic mice overexpressing activate form
of GSK 3β in the heart, the hypertrophic response to
calcineurin activation was severely impaired [81]. However,
it is interesting to note that transgenic mice overexpressingExperimental Diabetes Research 5
constitutively active form of GSK 3 (GSK3S9A/S21A knockin
mice) exhibit glomerular injury with proteinuria [82].
4.4. Emerging Target in Signaling. Deptor (DEPDC6-DEP
domain-containing and mTOR-interactive protein) is a
novel mTOR regulatory protein that interacts with mTOR
in both mTORC1 and mTORC2 and negatively regulates
mTOR activity [83, 84]. As discussed earlier, mTORC1 is a
central regulator of protein synthesis, ribosome biogenesis
and cell growth during diabetic kidney. A series of elegant
experiments based on loss-of-function strategy by Peterson
et al., [85] showed that Deptor interacts directly with both
mTOR complexes and inhibits downstream pathways regu-
lated by both complexes. Liu et al., [86] have shown that
enhanced interaction between mTOR and Deptor by re-
sveratrol, a known inhibitor of mTORC1 [70], negatively
regulated leucine-induced mTORC1 signaling in C2C12
myoblasts. Finally Deptor knockdown in vivo largely pre-
vented the atrophic response produced by immobilization
and, in part, this response was mediated by an increased
muscle protein synthesis [87]. Given its powerful role as
mTOR regulator, investigating the role of Deptor in diabetic
kidney disease may provide a new avenue for preventing
renal matrix accumulation.
5.MicroRNA (miR) inECMSynthesis
andAccumulation
miR microarray identiﬁed ﬁve miRs (192, 194, 204, 215,
and 216) that were highly expressed in human and mouse
kidney [88]. A seminal report by Kato et al. demonstrated
that the expression of miR 192, one of the highly expressed
miRs in the mouse kidney, is increased in the glomeruli
from db/db type 2 diabetic mice when compared to control
mice [89, 90] and in mesangial cells treated with high
glucose [91]. Upregulated expression of miR 192 occurs as
a consequence of TGF beta increment in diabetic glomeruli
which in turn increased the expression of Col1a2. Wang et
al. [91] demonstrated that in cultured human MCs exposed
to high glucose or TGF-beta, as well as in mouse DN models
in vivo, there was a signiﬁcant upregulation of miR-377 that
indirectlyledtoenhancedﬁbronectinproduction.Longetal.
[92] identiﬁed miR-29c expression in the kidney glomeruli
obtained from db/db type 2 diabetic mice in vivo and in
kidney microvascular endothelial cells and podocytes treated
with high glucose in vitro that has been found to enhance
ECM protein accumulation.
Recent studies have elucidated the role of miRs in con-
trolling translation [93]. miRs regulate gene expression by
inhibiting translation and/or by inducing degradation of
target messenger RNAs [94]. miRs bind directly to 3 un-
translated regions of speciﬁc transcripts and most often
directly repress translation; furthermore, an mRNA can be
simultaneously repressed by more than one miRNA species
or one miRNA can modulate more than one transcript [95].
Programmedcelldeath4(PDCD4),anendogenousinhibitor
of translation, has been identiﬁed as a target of miR 21, and
it will be interesting to investigate the role of miR 21 in
regulating ECM protein synthesis induced by diabetes. Dey
et al. [96] reported that high glucose and TGFβ increase
miR-21 and miR-214 in mesangial and proximal tubular
epithelial cells. These microRNAs target downregulation of
PTEN, an endogenous inhibitor of PI3 kinase dependent
downstream Akt activity, for translational repression. The
ﬁeld of miRs and their role in diabetic kidney disease are
an emerging ﬁeld of investigation, and further studies will
unravel the regulatory mechanism of these so-called “junk”
DNA sequences in the genetic code [97].
6. Epigenetic ModiﬁcationinECM Production
Epigenetics is deﬁned as mechanisms that aﬀect chromatin
structure and gene expression and dysregulation of the ep-
igenomecanalsoleadtodisease.Majorpathologicmediators
of diabetes such as hyperglycemia, inﬂammatory factors,
cytokines, and growth factors can lead to dysregulation of
epigenetics [98]. Epigenetic changes include DNA methy-
lation (covalent attachment of methyl groups at CpG
dinucleotides), histone modiﬁcations (acetylation, methyla-
tion, phosphorylation, and ubiquitination), and RNA-based
silencing. In the context of diabetic nephropathy, the altered
state of the epigenome may be the underlying mechanism
contributingtoa“metabolicmemory”thatresultsinchronic
inﬂammation and vascular dysfunction in diabetes even
after achieving glycaemic control [99–101]. Identiﬁcation
of genetic and epigenetic risk factors that modulate ECM
protein expression individually could provide the basis for
thedevelopmentofnoveltreatmentsandneweranimalmod-
els of diabetic nephropathy.
7. Renal ECM Metabolism in Animal Models of
Type2Diabetes
A higher proportion of individuals with type 2 diabetes are
found to have microalbuminuria and overt nephropathy
shortly after the diagnosis of their diabetes, because diabetes
is actually present for many years before the diagnosis.
This is why animal models of type 2 diabetes are very
important so that newer and speciﬁc markers of early kidney
injury could be identiﬁed before clinical diagnosis of the
disease.However,theseanimalscouldonlyrecapitulatesome
of the features of diabetic kidney disease seen in humans
[102, 103]. T2DM is a complex genetic disease comprising
many metabolic disorders with a common phenotype of
glucose intolerance. Cohen et al. [104]h a v ed o c u m e n t e d
that glomerular pathology in type 2 diabetic db/db mice
is accompanied by deﬁnable alterations in renal function,
which are similar in chronology and nature to those found in
human diabetes. Studies in db/db mice with type 2 diabetes
have shown that accumulation of the renal matrix protein
laminin-beta 1 is not associated with increase in its mRNA,
suggesting potential regulation by mRNA translation [54].
Since hyperglycemia is associated with hyperinsulinemia,
coinciding with the onset of laminin accumulation in the
kidney in db/db mice, augmented laminin mRNA translation
could be due to either elevated glucose or high insulin.6 Experimental Diabetes Research
If hyperinsulinemia was to be implicated in laminin reg-
ulation in type 2 diabetes, the renal parenchyma would
have to be responsive to insulin, unlike the liver which is
insulin resistant. This was investigated by Feliers and col-
leagues; they employed a series of tests examining the status
of insulin receptor activation and reported that kidney is
responsive to insulin at the same time when liver is resistant
to insulin in diabetic db/db mice [105]. These observations
steered a series of investigations that identiﬁed a novel
regulatory mechanism for ECM protein increment, mRNA
translation [14, 15, 32], and also raised the possibility that
hyperinsulinemia could participate in renal injury in type 2
diabetes.
Therearetwoothermodelsoftype2diabeteswhichshow
progression of diabetic kidney disease that resemble human
disease. The KKAy/Ta mice produced by transfection of the
yellow obese gene (Ay) into KK/Ta mice are obese, diabetic
mice that manifest hyperglycemia, hypertriglyceridemia, hy-
perinsulinemia, and microalbuminuria. KKAy mice devel-
oped hyperglycemia, hyperinsulinemia, and obesity after 16
weeks, with proteinuria, mesangial matrix accumulation,
GBM thickening, and tubular dilation. It was considered
a good animal model for the early pathology changes of
DN [106–108]. The MKR mice which transgenically express
mutantIGF-1R speciﬁcallyin skeletalmuscle develop insulin
resistance in fat and liver with rapidly progressive beta-cell
dysfunction and type 2 diabetes [109]. They exhibit early
onset of the disease phenotype as seen by insulin resistance
(as early as 4 weeks), fasting hyperglycemia (from 5 weeks),
and abnormal glucose tolerance (at 7–12 weeks), and they
develop kidney disease characterized by ECM accumulation
[110].
8. Management of DiabeticRenal Disease
Currently available therapies are not completely eﬀective in
arresting progression of diabetic kidney disease, especially
at more advanced stages of disease. Consistent with inves-
tigations discussed above [35], studies have shown that ACE
inhibitors and ARBs are beneﬁcial in reducing the progres-
sion of albuminuria in patients with type 2 diabetes [5,
72, 111]. Treatment with an ACE inhibitor has been shown
to normalize expression of laminin in murine mesangial
cells [112]. A recent report shows the use of antiﬁbrogenic
drugs that block TGF beta to be eﬀective in restoring
kidney function [113]. Although the angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers retard
the progression of diabetic nephropathy, they are not able
to halt the eventual development of end-stage renal disease
[114, 115]. One reason could be that pathological changes
in the kidney may already be in place preceding the clinical
diagnosis of diabetic nephropathy owing to the cumulative
eﬀects of postprandial hyperglycemic excursions, metabolic
syndrome, and insulin resistance in type 2 diabetes. We
need to take into consideration that several pathologic
processes work in consort to result in kidney injury in
diabetes. To date the usual investigational approach has been
linear, having adopted the traditional one-variable-at-a-time
model. Future investigations should apply a systems biology
approach to understand how multiple pathogenetic events
occurring simultaneously result in renal injury in diabetes.
9. Conclusion
Deregulation of protein synthesis, processing, and degra-
dation underlie the development of renal matrix changes
induced by hyperglycemia in type 2 diabetes. Thus, attenuat-
ing ECM accumulation and/or enhancing ECM degradation
is considered a prime target in the preventive treatment
of diabetic renal complications. In order to achieve this
objective identifying the molecular mechanisms by which
high glucose stimulates matrix protein synthesis is of
paramount importance. Understanding these mechanisms
may help develop early detection strategies and help identify
those subjects at risk of progressing to advanced kidney
derangement. While optimal control of hyperglycemia is a
highly desirable approach in the treatment of diabetic com-
plications including nephropathy, the diﬃculty in achieving
this goal due to inability to adhere to therapeutic regimens
and adverse eﬀects of intensive glucose control regimens
require us to ﬁnd additional therapeutic avenues. Such
interventions can only be developed by truly understanding
the pathogenesis of kidney injury in diabetes and identifying
viable therapeutic targets.
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